Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Intraperitoneal therapy: current questions

CFS 2011

Published: 24 Nov 2011

Views: 4070

Rating:

Save

Prof Franco Muggia – New York University Medical Center, USA

Prof Franco Muggia talks to ecancertv about the latest in intraperitoneal therapy. Giving cisplatin direct to the abdomen rather than intravenously. Talking at the 2011 Chemotherapy Foundation Symposium, New York.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Choosing the right patients for transplant

Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

Choosing the right patients for transplant ( Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof...

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy...

Prof Jean-Marc Classe - Nantes Université, Nantes, France

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes ( Prof Jean-Marc Classe - Nantes Université, Nantes, France )

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

Gynaecological cancer: New targets and immunotherapy developments ( Dr Mark Shahin - Jefferson Health, Philadelphia, USA )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer